Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia

Keyphrases

• COVID-19 100%
• B-cell Acute Lymphoblastic Leukemia (B-ALL) 100%
• Severe COVID-19 100%
• COVID-19 Virus 100%
• Virus Reactivation 100%
• Polymerase Chain Reaction 60%
• Cytarabine 40%
• Nasal 40%
• Rituximab 40%
• Dasatinib 40%
• Immunosuppressive Therapy 20%
• Anticoagulation 20%
• Lymphocytes 20%
• New York City 20%
• Lymphopenia 20%
• Intensive Care Unit 20%
• Leukemia 20%
• Antibody Titer 20%
• Young Female 20%
• CD20+ 20%
• Reinfection 20%
• Inflammatory Markers 20%
• Stable Conditions 20%
• Lowercase 20%
• Chest CT 20%
• Convalescent Plasma 20%
• Leukemia Therapy 20%
• Ground-glass Opacity 20%
• COVID-19 Antibody 20%
• Viral Reactivation 20%
• Severe COVID-19 Pneumonia 20%
• Second Infection 20%
• High-flow Nasal Cannula 20%
• Recovered COVID-19 Patients 20%

Medicine and Dentistry

• COVID-19 100%
• Virus Reactivation 100%
• Acute B-Cell Lymphoblastic Leukemia 100%
• Severe Acute Respiratory Syndrome Coronavirus 2 80%
• Polymerase Chain Reaction 60%
• Leukemia 40%
• Cytarabine 40%
• Rituximab 40%
• Dasatinib 40%
• Immunosuppressive Treatment 20%
• Anticoagulation 20%
• Infection 20%
• Lymphocytopenia 20%
• CD20 20%
• Intensive Care Unit 20%
• Reinfection 20%
• Ground Glass Opacity 20%
• Nasal Cannula 20%
• Lymphocyte 20%